Secukinumab alleviates cognitive impairment by attenuating oxidative stress and neuronal apoptosis via the IL-17RA/AKT/ERK1/2 pathway in a rat model of sepsis
Authors:
- 4 November 2022
- journal article
- research article
- Published by Elsevier in Experimental Neurology
- Vol. 359, 114263
Abstract
No abstract availableKeywords
Funding Information
- State Key Laboratory of Medical Neurobiology
- Ministry of Education - Singapore
- Fudan University
This publication has 51 references indexed in Scilit:
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic ArthritisNew England Journal of Medicine, 2015
- The role of IL-17 in CNS diseasesActa Neuropathologica, 2015
- Secukinumab: First Global ApprovalDrugs, 2015
- Poststroke Neuropsychiatric Symptoms: Relationships with IL-17 and Oxidative StressBioMed Research International, 2014
- The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytesGlia, 2014
- Acute Brain Inflammation and Oxidative Damage Are Related to Long-Term Cognitive Deficits and Markers of Neurodegeneration in Sepsis-Survivor RatsMolecular Neurobiology, 2013
- Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic strokeBlood, 2012
- Immunodesign of experimental sepsis by cecal ligation and punctureNature Protocols, 2008
- Production and functions of IL-17 in microgliaJournal of Neuroimmunology, 2008
- Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity.Journal of Experimental Medicine, 1993